metaMe Health, Inc. (metaMe), a Prescription Digital Therapeutics (PDT) company and developer of ReguloraR, the first FDA-authorized PDT specifically for abdominal pain associated with Irritable Bowel Syndrome (IBS) in adults, today announced that it has received $2.2M in funding in a bridge round led by Hyde Park Angels (HPA), with additional investments from individuals. The funds will be used to continue preparation for Regulora’s market launch and to build out metaMe’s commercial infrastructure.